Paul F. Lizzul
Known title: Chief Medical OfficerCIK: 0001711462
Associated companies
Transaction History
| ANAB | ▼ Sell | Open Market | 3,650 | $163K | 1/8/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 8,525 | — | 1/7/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 2,235 | $101K | 1/7/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,145 | — | 1/6/2026 | View on chart |
| ANAB | ▼ Sell | Open Market | 4,219 | $183K | 1/5/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 10,555 | — | 1/3/2026 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 1,500 | $28K | 12/22/2025 | View on chart |
| ANAB | ▼ Sell | Open Market | 1,500 | $75K | 12/22/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,145 | — | 1/6/2025 | View on chart |
| ANAB | ▼ Sell | Tax Withholding | 2,261 | $35K | 1/6/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 10,555 | — | 1/3/2025 | View on chart |
| ANAB | ▼ Sell | Tax Withholding | 4,336 | $63K | 1/3/2025 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 1,500 | $28K | 9/23/2024 | View on chart |
| ANAB | ▼ Sell | Open Market | 1,500 | $58K | 9/23/2024 | View on chart |
| ANAB | ▼ Sell | Open Market | 2,220 | $86K | 9/16/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,000 | — | 9/14/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 2,000 | $37K | 8/14/2024 | View on chart |
| ANAB | ▼ Sell | Open Market | 2,000 | $80K | 8/14/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 1,500 | $28K | 7/18/2024 | View on chart |
| ANAB | ▼ Sell | Open Market | 1,500 | $53K | 7/18/2024 | View on chart |
| ANAB | ▼ Sell | Open Market | 2,554 | $56K | 1/8/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,145 | $0 | 1/6/2024 | View on chart |
| ANAB | ▲ Buy | Option Exercise | 6,000 | — | 9/14/2023 | View on chart |
| ANAB | ▼ Sell | Open Market | 2,105 | $41K | 9/14/2023 | View on chart |
| ANAB | ▲ Buy | Grant | 964 | $21K | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AnaptysBio News Mixes Valuation Views With Litigation Risks
Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.
AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.